Balentine LLC Immuno Gen, Inc. Transaction History

Balentine LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 02, 2020	SELL	$3.45 - $4.89 $1,362 - $1,931	-395 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.32 - $5.34 $1,311 - $2,109	395 New	395 $2,000
Q1 2019 May 16, 2019	SELL	$2.41 - $5.91 $1,335 - $3,274	-554 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $4,764 - $6,238	554 New	554 $5,000
Q1 2018 May 16, 2018	SELL	$6.7 - $12.95 $12,743 - $24,630	-1,902 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$5.4 - $8.47 $10,270 - $16,109	1,902	1,902 $15,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

Stay updated on Balentine LLC with notifications on news.